Enteropathy-type T-cell lymphoma (ETCL) is an uncommon subtype of peripheral T-cell lymphoma (PTCL) and occurs predominantly in the jejunum or ileum. It is usually associated with coeliac disease but cases of ETCL without a prior diagnosis of coeliac disease have been also reported. Patients present with abdominal pain and malabsorption, and occasionally with intestinal perforation. The clinical course of ETCL is very unfavourable due to a poor performance status at diagnosis, high risk of intestinal perforation during treatment and high risk of relapse. Overall survival rates of less than 20% at 5 years were reported in a single institution study. 1 Here, we report a successful case of unrelated cord blood transplantation (CBT) using reduced-intensity conditioning (RIC) in a patient with refractory ETCL. To our knowledge, this is the first report of CBT as treatment of ETCL.
A 47-year-old woman was admitted to our hospital because of abdominal pain and weight loss. Computed tomography (CT) scan demonstrated marked wall thickening of multiple segments of the small intestine and colon with mesenteric lymphadenopathy and massive ascites. Endoscopic examination showed extensive ulcerating lesions involving the duodenum, stomach and colon. Biopsies from these lesions showed diffuse infiltration with monomorphic medium-sized lymphocytes throughout the affected intestinal wall with prominent intraepithelial infiltration; the immunophenotype was CD2
À and partially positive for Granzyme B. EBV-encoded small nuclear early region (EBER) was negative. TCRg gene rearrangement was detected by PCR analysis. On the basis of the histological and immunological findings, the patient was diagnosed with ETCL. Cytological analysis of ascitic fluid also revealed the presence of lymphoma cells. Although she had no apparent history of coeliac disease, she showed the HLA-DQA1*0501 genotype and a positive result against antigliadin antibodies, both of which characterize coeliac disease.
Despite two cycles of EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) chemotherapy, 2 a CT scan demonstrated a marked increase of lesions at the third portion of the duodenum. Her status was regarded as that of progressive disease and so the chemotherapy regimen was changed to ICE (ifosfamide, etoposide and carboplatin). 3 After delivering three cycles of ICE chemotherapy, her symptoms derived from malabsorption were resolved, although fluorodeoxyglucosepositron emission tomography (FDG-PET) still showed abnormal uptake in the duodenum. After four cycles of ICE, no apparently abnormal metabolic activity was detected by PET. However, endoscopic examination suggested residual disease because of remaining severe stenosis at the third portion of the duodenum. Since she was considered to have achieved only a partial remission, we intended to perform allogeneic SCT (allo- ) on days À3 and À2 and total body irradiation on day À1 (400 cGy in two fractions). Tacrolimus (0.03 mg/kg/day, continuous infusion from day À1) was used for GVHD prophylaxis. G-CSF was started on day þ 1. Engraftment was confirmed on day þ 14 without significant regimen-related toxicity. Chimaerism analysis using variable number of tandem repeats performed on day þ 29 showed complete donor-type engraftment.
On day þ 44, FDG-PET demonstrated further abnormal accumulation in the duodenum (Figure 1) , and lymphoma cells were confirmed in an endoscopical biopsy specimen. Since she showed no apparent signs of acute GVHD, we rapidly tapered tacrolimus thereafter and stopped it on day þ 57. FDG-PET performed on day þ 138 became completely normal. Endoscopic examination on day þ 266 showed no evidence of disease in the duodenum, suggesting a graft-versus-lymphoma effect. The patient is currently alive, in sustained CR with a good performance status at the last follow-up of 11 months after transplantation, with no signs of chronic GVHD.
The prognosis of ETCL is extremely poor. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen alone usually results in a poor response or frequent relapse, which necessitate more effective alternative treatment options. The use of autologous SCT (auto-SCT) has been successful in a small prospective trial for patients with ETCL in first remission but has had poor results in a series of relapsed cases. subtypes of PTCL. 4, 5 As with other haematological malignancies, there are fewer relapses with allo-SCT than auto-SCT in PTCL, but treatment-related mortality (TRM) is higher in allo-SCT that employs intense myeloablative conditioning. 6 RIC regimens are less toxic than myeloablative regimens and allow the treatment of older patients and those with comorbidities. A pilot trial with allo-SCT using RIC in primary refractory or relapsed nodal PTCL reported a TRM of 6% with a 3-year overall survival of 81%. 7 In our case, it seemed unlikely that standard-dose chemotherapy alone would have conferred long-term survival. Since fully myeloablative chemotherapy was considered to be inappropriate because of impaired nutritional status, we performed CBT using RIC while the patient was in relatively good clinical condition. Although local regrowth of lymphoma cells in the duodenum was observed shortly after CBT, these disappeared spontaneously at 6 months after transplantation. There are several reports of transient deterioration in residual disease until the development of an effective graftversus-tumour effect after allo-SCT using RIC. 8 In our case, rapid withdrawal of tacrolimus may have hastened the occurrence of a graft-versus-lymphoma effect.
Although a longer follow-up period is required to confirm its true efficacy, unrelated CBT for refractory ETCL was feasible using RIC, and the promising clinical course of this patient suggests the existence of a graftversus-lymphoma effect against ETCL.
K Chonabayashi, T Kondo, Y Tanaka, T Ichinohe, T Ishikawa and T Uchiyama Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan E-mail: kchona@kuhp.kyoto-u.ac.jp Figure 1 Fluorodeoxyglucose-positron emission tomography (FDG-PET) 44 days after transplantation. FDG uptake in the duodenum reappeared (arrowheads). Endoscopic examination still showed severe stenosis at the third portion of the duodenum, and lymphoma cell presence was confirmed in the biopsy specimen.
